Please use the navigation arrows on the side to select content to view.
"When Bailey was born we were very concerned about his low birth weight. He was so small and we didn’t know what it would mean for his development."
"My son Bailey was born at 27 weeks gestation. He was tiny and had to fight for survival. Bailey received parenteral nutrition as part of a package of care that supported his growth and development at the start of his life."
EPA and DHA play a crucial role in neurodevelopment and immune function, and have been shown to be increased in very low birth weight neonatal patients receiving SMOFlipid, compared with soya-bean oil emulsion.2
Box and whisker plots indicate medians, interquartile ranges and the 2.5th and 97.5th percentiles
*There was a significant difference (p < 0.05) between the study group and the control group on Day 6
**There was a significant difference (p < 0.05) between the study group and the control group on Day 14
***There was a significant change from Day 6 to 14 (p < 0.05)2
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid
Bailey gained 250g in weight and 15mm in head circumference over 14 days.
After 14 days Bailey was receiving full enteral nutrition.
"Parenteral nutrition was really important in the early days of Bailey’s life. It was reassuring to know that he was receiving the nutrients he needed to keep growing and developing. He’s now a happy healthy little boy, you wouldn’t know that he was born prematurely."
For over 10 years, we’ve worked with the same trusted 4-oil formulation.
Bailey is one example of the millions of patients who have been prescribed SMOFlipid.6
As times are changing, we’re working with clinicians and patients to help provide the support they need. We’re part of a wider package of care, aiming to improve the lives of adults, children and infants.
They are why we keep going.
For the next 10 years, and beyond.
Speak with your Fresenius Kabi representative to discuss how SMOFlipid can help support your neonatal patients.
Contact Us